We are live on
!
Find out more
PA
Perceptive Advisors Portfolio holdings
AUM
$6.66B
1-Year Est. Return
360.84%
This Fund
S&P 500
This Quarter
Est. Return
+21.92%
1 Year Est. Return
+360.84%
3 Year Est. Return
+1,707.27%
5 Year Est. Return
+3,210.42%
10 Year Est. Return
+53,055.89%
AUM
$1.44B
AUM Growth
+$302M
(+27%)
Cap. Flow
+$191M
Cap. Flow
% of AUM
13.26%
Top 10 Holdings %
Top 10 Hldgs %
50.32%
Holding
229
New
57
Increased
37
Reduced
31
Closed
55
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
NXTM
NxStage Medical Inc.
NXTM
|
+$24.7M |
| 2 |
MDVN
MEDIVATION, INC.
MDVN
|
+$23.8M |
| 3 |
GBT
Global Blood Therapeutics, Inc.
GBT
|
+$18.4M |
| 4 |
STJ
St Jude Medical
STJ
|
+$16.6M |
| 5 |
LJPC
La Jolla Pharmaceutical Company
LJPC
|
+$11.4M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AGN
Allergan plc
AGN
|
+$41.5M |
| 2 |
Humana
HUM
|
+$20.1M |
| 3 |
FPRX
Five Prime Therapeutics, Inc.
FPRX
|
+$12.4M |
| 4 |
Baxter International
BAX
|
+$9.04M |
| 5 |
XLRN
Acceleron Pharma
XLRN
|
+$6.5M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 78.68% |
| 2 | Consumer Staples | 0.52% |
| 3 | Consumer Discretionary | 0.08% |
| 4 | Financials | 0.04% |
| 5 | Industrials | 0.04% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
PUT
Sarepta Therapeutics
SRPT
$2B
| $145M | 10.07% |
+7,619,300
| New | +$141M |
|
2
Neurocrine Biosciences
NBIX
$15.6B
| $127M | 8.82% |
2,797,967
+77,000
| +3% | +$3.55M |
|
|
TSRO
3
DELISTED
TESARO, Inc.
TSRO
| $96.1M | 6.66% |
1,143,615
+44,956
| +4% | +$2M |
|
|
FOLD
4
DELISTED
Amicus Therapeutics
FOLD
| $83.2M | 5.77% |
15,239,444
| – | – |
|
|
5
Sarepta Therapeutics
SRPT
$2B
| $71.8M | 4.98% |
3,767,316
-65,812
| -2% | -$1.22M |
|
6
Travere Therapeutics
TVTX
$6.32B
| $58.4M | 4.05% |
3,279,380
+280,000
| +9% | +$4.53M |
|
|
MDVN
7
DELISTED
MEDIVATION, INC.
MDVN
| $45.8M | 3.18% |
760,000
+420,000
| +124% | +$23.8M |
|
|
GBT
8
DELISTED
Global Blood Therapeutics, Inc.
GBT
| $36.6M | 2.54% |
2,207,668
+910,200
| +70% | +$18.4M |
|
|
ARAV
9
DELISTED
Aravive, Inc. Common Stock
ARAV
| $31.4M | 2.17% |
472,626
| – | – |
|
|
NXTM
10
DELISTED
NxStage Medical Inc.
NXTM
| $30M | 2.08% |
+1,382,410
| New | +$24.7M |
|
11
Iovance Biotherapeutics
IOVA
$3.82B
| $29.3M | 2.03% |
3,611,976
+824,720
| +30% | +$5.18M |
|
12
Xencor
XNCR
$2.18B
| $29M | 2.01% |
1,529,574
-275,210
| -15% | -$3.77M |
|
13
PUT
State Street SPDR S&P Biotech ETF
XBI
$11.8B
| $27M | 1.87% |
+500,000
| New | +$27.4M |
|
|
NVRO
14
DELISTED
NEVRO CORP.
NVRO
| $26.9M | 1.87% |
365,229
+16,629
| +5% | +$1.13M |
|
|
CPXX
15
DELISTED
CELATOR PHARMACEUTICALS INC. COMMON STOCK
CPXX
| $25.3M | 1.75% |
838,400
-261,600
| -24% | -$5.31M |
|
|
LJPC
16
DELISTED
La Jolla Pharmaceutical Company
LJPC
| $21.3M | 1.48% |
1,332,815
+633,300
| +91% | +$11.4M |
|
|
XLRN
17
DELISTED
Acceleron Pharma
XLRN
| $20.5M | 1.42% |
603,036
-200,000
| -25% | -$6.5M |
|
|
18
CALL
Sarepta Therapeutics
SRPT
$2B
| $18.7M | 1.29% |
979,200
+429,200
| +78% | +$7.95M |
|
|
STJ
19
DELISTED
St Jude Medical
STJ
| $18.2M | 1.26% |
+233,000
| New | +$16.6M |
|
|
DBVT
20
DBV Technologies
DBVT
$941M
| $17.8M | 1.24% |
54,670
+13,000
| +31% | +$4.21M |
|
|
QTNT
21
DELISTED
Quotient Limited Ordinary Shares
QTNT
| $17.4M | 1.21% |
56,227
+1,500
| +3% | +$573K |
|
22
Evolent Health
EVH
$553M
| $16.8M | 1.16% |
873,064
+254,134
| +41% | +$3.49M |
|
23
Talphera
TLPH
$63.8M
| $16.1M | 1.12% |
299,788
| – | – |
|
|
DERM
24
DELISTED
Dermira, Inc.
DERM
| $13.5M | 0.94% |
462,000
-50,000
| -10% | -$1.38M |
|
|
VBIV
25
DELISTED
VBI Vaccines, Inc. New Common Stock (Canada)
VBIV
| $12.1M | 0.84% |
101,948
-6,731
| -6% | -$674K |
|
Similar funds
QP
FCBT
RWM
AWA
WHRC
LSERS
CAG
MCM
Perceptive Advisors's Q2 2016 Portfolio in Review
As of Q2 2016, Perceptive Advisors held 229 positions worth $1.44B, up 27% from $1.14B the previous quarter. Its ten largest holdings account for 50% of the portfolio.
Perceptive Advisors deployed $191M of net new capital in Q2 2016, opening 57 new positions and adding to 37 existing holdings. Its largest new stake was NxStage Medical Inc.: 1,382,410 shares worth $30M.
By sector, the portfolio is most concentrated in Healthcare at 79% of assets, down from 93% a quarter earlier, followed by Consumer Staples and Consumer Discretionary.
On the sell side, the largest reduction was Five Prime Therapeutics, Inc., an estimated $12.4M trimmed.
- Perceptive Advisors's largest Q2 2016 buy was NxStage Medical Inc.: 1,382,410 shares worth $30M.
- Perceptive Advisors added most to MEDIVATION, INC. in Q2 2016, an estimated $23.8M increase.
- Perceptive Advisors's biggest Q2 2016 reduction was Five Prime Therapeutics, Inc., cutting an estimated $12.4M.
- Perceptive Advisors fully exited Allergan plc in Q2 2016, selling an estimated $41.5M.
- Perceptive Advisors's ten largest holdings make up 50% of its $1.44B portfolio in Q2 2016.
- Perceptive Advisors opened 57 new positions and closed 55 in Q2 2016.
- Perceptive Advisors's portfolio value rose 27% quarter-over-quarter to $1.44B.
Based on Perceptive Advisors's 13F filing for Q2 2016, filed 11 Aug 2016.